Shares rose for a second day, in a rally sparked by rival Eli Lilly (LLY) reporting less-than-stellar trial results for an ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

By Twesha Dikshit (Reuters) -European stocks edged higher on Friday, led by upbeat corporate earnings and a jump in Novo ...

CNBC's Silvia Amaro takes a look at the rise and fall in Novo Nordisk shares. Donald Trump's executive order changing 401 ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a ...

Novo Nordisk remains the GLP-1 leader with over 65% market share. Read an in-depth BVO stock analysis and why we rate it as a ...

Novo Nordisk continues to deliver double-digit revenue and profit growth, driven by both its diabetes and obesity drug ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed its fortunes.

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...